Summary
- Closed for EoI
- Profile Type
- Research & Development Request
- POD Reference
- RDRTR20251211002
- Term of Validity
- 11 December 2025 - 11 December 2026
- Company's Country
- Turkey
- Type of partnership
- Research and development cooperation agreement
- Targeted Countries
- Malta
- Ireland
- France
- Poland
- Portugal
- Slovakia
- Estonia
- Switzerland
- Netherlands
- Czechia
- Austria
- Germany
- Latvia
- South Africa
- Canada
- Denmark
- Sweden
- Hungary
- Finland
- Italy
Contact the EEN partner nearest to you for more information.
Find my local partner
General information
- Short Summary
- The EV-ResistOmics project aims to isolate and characterize bacterial extracellular vesicles (bEVs) from antibiotic-resistant and susceptible strains across multiple countries. Using standardized protocols, partners will generate integrated multi-omics datasets, including genomics, transcriptomics, lipidomics, and metabolomics, to identify EV-associated biomarkers of resistance and explore their diagnostic or therapeutic potential. The project seeks collaborators in microbiology, EV charactrz.
- Full Description
-
Target Call: OH-AMR Joint transnational call 2026
Project Topic: Multi-Omics Characterization of Bacteria-Derived Extracellular Vesicles from Antibiotic-Resistant Strains (EV-ResistOmics)
Antibiotic-resistant bacteria deploy diverse molecular mechanisms to adapt to antimicrobial pressures. Recent findings highlight that bacteria-derived extracellular vesicles (bEVs) serve as vehicles for transferring resistance determinants, regulatory RNAs, lipids, and metabolites that modulate pathogenicity and therapeutic response. However, comprehensive multi-omics datasets comparing bEVs across different resistance phenotypes remain extremely limited.
This project proposes a multi-country, coordinated initiative to generate, share, and analyze bEV multi-omics datasets derived from bacterial strains with distinct resistance profiles, supporting the OH-TREAT goal of advancing innovative treatment solutions and improving protocol adherence through mechanistic understanding.
The Ev-Resist Omics Project aims to isolate and characterize bacterial extracellular vesicles (bEVs) from antibiotic-resistant and susceptible bacterial strains, and to perform integrated genomic, transcriptomic, lipidomic, and metabolomic analyses to identify signatures associated with resistance and treatment response
Specific Objectives
• Collect and share bacterial strains with diverse resistance phenotypes across participating countries (subject to legal and biosafety frameworks).
• Standardize and harmonize bEV isolation protocols (ultracentrifugation, SEC, density gradients).
• Generate a comprehensive multi-omics dataset, including:
• Whole-genome sequencing of bacterial isolates
• Transcriptomic profiling (bacterial & EV-associated RNA)
• Lipidomic analysis of EV membranes
• Metabolomic profiling of EV cargo
• Integrate multi-omics data using advanced bioinformatics pipelines to identify EV-associated biomarkers of resistance.
• Explore diagnostic or therapeutic relevance of identified molecular signatures.
Methodological Overview
Each partner isolates local clinical or reference strains (e.g., MRSA, ESBL-producers, carbapenem-resistant strains, VRE, etc.).Countries exchange strains or EV preparations, depending on regulatory feasibility.Centralized or distributed omics analysis platforms generate WGS, RNA-seq, lipidomics, and metabolomics data.Bioinformatics partners integrate datasets through:
• Differential expression and pathway analyses
• Network modeling
• Machine-learning–based biomarker discovery
Expected Results
• A pan-European, high-resolution multi-omics atlas of bEVs from resistant and susceptible isolates.
• Identification of EV-linked resistance signatures (RNAs, lipids, metabolites, protein markers).
• Candidate biomarkers for diagnostic or monitoring tools.
• Mechanistic insights supporting improved therapeutic guidance and adherence modelling.
Consortium Structure
• Lead institution: EV isolation standardization + coordination
• Country-level microbiology nodes: strain isolation, phenotyping, EV preparation
• Central or distributed omics hubs: genomics, transcriptomics, lipidomics, metabolomics
• Bioinformatics hub: integrative modeling and biomarker discovery
• Adherence/clinical partners (optional): linking omics findings to treatment optimization - Advantages and Innovations
- The EV-ResistOmics project offers a unique opportunity to generate the first pan-European multi-omics atlas of bacterial extracellular vesicles from antibiotic-resistant and susceptible strains. By standardizing EV isolation protocols and integrating genomics, transcriptomics, lipidomics, and metabolomics data, the project will uncover novel EV-associated biomarkers of resistance. This knowledge can directly inform diagnostics and therapeutic strategies, while the transnational collaboration ensures access to diverse bacterial strains, harmonized methodologies, and advanced bioinformatics expertise, creating a strong foundation for innovative antimicrobial research.
- Technical Specification or Expertise Sought
-
We are seeking collaborators with the following technical specifications and characteristics:
A. Microbiology & Clinical Partners
Institutions with the ability to supply bacterial strains with well-characterized resistance profiles, proven capacity for strain exchange under appropriate biosafety and legal/ethical frameworks, and strong expertise in microbial culture, antimicrobial resistance assays, and phenotype validation.
B. EV Isolation & Characterization Partners
Laboratories with established, reproducible workflows for bacterial extracellular vesicle (EV) isolation, and access to advanced EV characterization platforms such as TEM, NTA, and proteomic and/or molecular characterization methods.
C. Multi-Omics Platforms
Core facilities or research groups offering integrated multi-omics capabilities, including:
Genomics: whole-genome sequencing (WGS), variant calling, and resistance gene analysis
Transcriptomics: RNA-seq for both bacteria and EVs
Lipidomics: LC–MS/MS or GC–MS workflows
Metabolomics: untargeted and/or targeted MS-based metabolomics
D. Bioinformatics and Data Integration Partners
Teams with expertise in developing and running multi-omics integration pipelines, advanced computational modeling (including machine learning and network biology approaches), and data management in full compliance with FAIR principles (Findable, Accessible, Interoperable, Reusable). - Stage of Development
- Under development
- Sustainable Development Goals
- Goal 3: Good Health and Well-being
- Goal 17: Partnerships to achieve the Goal
- IPR status
- IPR granted
- IPR notes
- IPR has already been granted
Partner Sought
- Expected Role of a Partner
-
We are seeking collaborators in the following categories:
• A.Microbiology & Clinical Partners
o Ability to supply bacterial strains with well-characterized resistance profiles
o Capacity for strain exchange under appropriate biosafety and legal frameworks
o Expertise in culture, resistance assays, and phenotype validation
• B. EV Isolation & Characterization Partners
o Established workflows for bacterial EV isolation
o TEM, NTA, proteomic or molecular EV characterization capabilities
• C. Multi-Omics Platforms
o Genomics: WGS, variant calling, resistance gene analysis
o Transcriptomics: RNA-seq (bacterial and EV)
o Lipidomics: LC–MS/MS or GC–MS workflows
o Metabolomics: untargeted or targeted MS workflows
• D. Bioinformatics and Data Integration Partners
o Multi-omics integration pipelines
o Advanced modeling, machine learning, network biology
o Data management in compliance with FAIR principles - Type and Size of Partner
- SME 11-49
- R&D Institution
- SME 50 - 249
- Big company
- University
- Type of partnership
- Research and development cooperation agreement
Call details
- Framework program
- Horizon Europe
- Call title and identifier
-
European Partnership on One Health Antimicrobial Resistance
- Submission and evaluation scheme
-
This is a two stage call
- Anticipated project budget
-
30000000
- Coordinator required
-
No
- Deadline for EoI
- Deadline of the call
- Project duration in weeks
-
144
- Web link to the call
- https://ohamr.eu/calls/call-2026-new-treatments-to-tackle-amr/
- Project title and acronym
-
Isolation and performing multi-omics characterization of bacterial extracellular vesicles from antibiotic-resistant strains.
- Horizon Europe
Dissemination
- Technology keywords
- 06002008 - Microbiology
- 06002001 - Biochemistry / Biophysics
- 06001012 - Medical Research
- 06002002 - Cellular and Molecular Biology
- Market keywords
- 05001005 - Molecular diagnosis
- 05001003 - Differential diagnosis
- Sector Groups Involved
- Health
- Targeted countries
- Malta
- Ireland
- France
- Poland
- Portugal
- Slovakia
- Estonia
- Switzerland
- Netherlands
- Czechia
- Austria
- Germany
- Latvia
- South Africa
- Canada
- Denmark
- Sweden
- Hungary
- United Kingdom
- Finland
- Italy